The Carlyle Group has bolstered its healthcare investment capabilities with the acquisition of life sciences investment manager Abingworth, according to a report by AlternativesWatch.
Financial details of the transaction, which is expected to close later this year, have not been disclosed.
The report quotes “officials at the $301 billion Carlyle” as saying that the acquisition now allows Carlyle to operate across the life sciences and healthcare investment spectrum from venture capital to through to buyouts.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.